MedTrace Logo

A Study to Determine Eligibility for CAH-301 (A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) [NCT04783181])

NCT05101902 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2024-09-19

No results posted yet for this study

Summary

This pre-screening study is designed to determine potential eligibility of adults with classic CAH due to 21-hydroxylase deficiency (21-OHD) for participation in the CAH-301 \[NCT04783181\] gene therapy trial with BBP-631.

Conditions

  • Congenital Adrenal Hyperplasia

Interventions

OTHER

Pre-Screening

No intervention given

Sponsors & Collaborators

  • Adrenas Therapeutics Inc

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2024-08-07
Completion
2024-08-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05101902 on ClinicalTrials.gov